Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Booms, Busts, and Recoveries -- Ignore unavailable to you. Want to Upgrade?

To: smolejv@gmx.net who wrote (31483)	4/14/2003 4:22:38 PM
From: jim black	Read Replies (1) \| Respond to of 74559

OT/OT/OT!!Yes, humbling in a way to drive me from the field except for fun. The Bernouli brothers posed the brachistochrome problem and figured they'd wait for months. The day after the problem was posed a certain fellow involved in alchemy at that part of his life, wasting his time of course, solved it over an evening. His name was Isaac Newton. The Bernoulli brothers said something self-effacing to the effect that they recognized the lion by his print...absolutely humbling. And Ramanujan...no formal training at all...a mutation of neuronal maturation perhaps, definitely wired differrently than the rest of us. We should probably be doing this chatter in private...sorry thread Jim Black

To: smolejv@gmx.net who wrote (31483)	4/15/2003 10:44:13 AM
From: jim black	Read Replies (1) \| Respond to of 74559

Dolinar, down to business for a change rather than my usual rants: What is your take on the German company Merz? I cannot find it listed on this side of the pond but they may have a blockbuster in memantine, probably to be marketed here in the States through Forest Labs. The results of the drug were reviewed in an American Academy of Neurology annual meeting in Oahu, Hawaii about three weeks ago, previously reviewed in January's New England Journal of Medicine and it has everyone in my specialty very optimistic. I do not know if the biotech NTI, a co-sponsor is a play or not. Memantine has been proven the only treatment for moderately advanced Alzheimer's disease in combination with Aricept (which we get good results with ONLY if used very early in the disease). As most of you who pay any attention to my rants on biotechs and drug companies in general I am generally not sanguine about drug company prospects ( always priced too high and who is going to pay for the damned drugs since they always cost a fortune?) but memantine if used as a play in the right sized drug company could be a blockbuster play. My last comment about a blockbuster drug was Avodart (GlaxoWelcomm) but GLX is such a huge company that a billion+ drug like Avodart will probably not make a ripple. Avodart shrinks prostate tissue enough to threaten the future of urologists who rely on TUR's (prostate surgey for older men) AND inhibits hair loss by acting a subtype ot the dihydrotestosterone receptor. So a heads up on Forest Labs, NTI and possibly Merz in Deutchland were we here able to buy it. Disclaimer: I am investigating but do not now own any of these companies and I am one pessimistic old fart when it comes to drug companies in general for their generally outrageous pe's adn growth rates, hence their PEG's , all just FWIW. Memantine is impressive in trials and will probably be available in USA soon and I as a practioner will be using it hand over fist if it is affordable. Jim Black